Research Article

Sex-Specific Associations of Trimethylamine-N-Oxide and Zonulin with Signs of Depression in Carbohydrate Malabsorbers and Nonmalabsorbers

Sophie Meinitzer,1 Andreas Baranyi,2 Sandra Holasek,3 Wolfgang J. Schnedl,4 Sieglinde Zelzer,5,1 Harald Mangge,1 Markus Herrmann,1 Andreas Meinitzer,1 and Dietmar Enko1,5

1Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria
2Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, 8036 Graz, Austria
3Department of Immunology and Pathophysiology, Medical University of Graz, 8010 Graz, Austria
4Practice for General Internal Medicine, 8600 Bruck/Mur, Austria
5Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Hochsteiermark, 8700 Leoben, Austria

Correspondence should be addressed to Dietmar Enko; enko.dietmar@gmx.at

Received 12 October 2019; Revised 8 December 2019; Accepted 23 December 2019; Published 7 January 2020

Academic Editor: Anja Hviid Simonsen

Copyright © 2020 Sophie Meinitzer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The microbiome-derived trimethylamine-N-oxide (TMAO) and the intestinal permeability marker zonulin are considered to be linked with depression. Moreover, carbohydrate malabsorption (CMA) was shown to be associated with signs of depression. This study is aimed at investigating possible sex-specific associations between TMAO and zonulin and the presence of depressive signs in individuals with and without CMA.

Methods. Serum concentrations of TMAO and zonulin were determined in 115 and 136 individuals with the presence or absence of CMA. All 251 study participants underwent lactase gene C/T-13910 polymorphism genotyping and fructose H2/CH4 breath testing. Additionally, they filled in the Beck Depression Inventory (BDI-II) questionnaire.

Results. The median TMAO and zonulin serum concentrations were 2.66 (1.93–4.14) μmol/L and 40.83 (34.73–47.48) ng/mL. Serum TMAO levels were positively correlated with depressive symptoms (P = 0.011, ρ = 0.160). The strongest correlations were observed in 87 females (P = 0.010, ρ = 0.274) and 49 males (P = 0.027, ρ = 0.315) without CMA, whereas 115 patients with CMA showed no significant correlations. Zonulin tended to be negatively correlated with the BDI-II score in 49 males without CMA (P = 0.062, ρ = −0.269).

Conclusion. This study demonstrates a positive correlation between the serum TMAO concentrations and the severity of depressive symptoms in females and males without CMA. Serum zonulin levels were negatively correlated with signs of depression in males without CMA. These findings suggest a gender-specific relationship between the serum TMAO and zonulin concentrations, depression, and CMA.

1. Introduction

In recent years, the gut-brain axis, which consists of interactions between the gut microbiome and the brain, has gained substantial attention. The main principal mechanisms of this complex bidirectional communication comprise modulation of the gut-blood barrier (GBB), alteration in intestinal motility, mucosal immunoregulation, and the production of local neurotransmitters and bacterial metabolites [1].
2. Materials and Methods

2.1. Study Design. A total of 251 consecutive ambulatory patients, who were admitted to the outpatient clinic for CMA testing, were included in this study. All study participants underwent LCT genotyping (C/T\textsubscript{13910} Polymorphism) and fructose H\textsubscript{2}/CH\textsubscript{4} breath testing to identify individuals with lactose and fructose malabsorption. Blood sampling was performed after an overnight fasting state in the morning between 08:00 and 10:00 a.m. evaluating the serum concentrations of TMAO and zonulin. Additionally, all study participants filled in the Beck Depression Inventory (BDI-II) questionnaire [19].

The inclusion criteria for this study were consecutive individuals referred to our outpatient clinic with suspected CMA, a minimum age of 18 years, and an obligatory overnight fasting and nonsmoking period. Individuals with an antibiotic-based therapy or colonoscopy at least 4 weeks before the H\textsubscript{2}/CH\textsubscript{4} breath test and patients with an acute or chronic inflammatory bowel disease were excluded from the study.

All study participants provided their written informed consent. Approval was obtained from the local Ethical Committee of the Johannes Kepler University Linz (Linz, Austria). The study was carried out in accordance to the current version of the Declaration of Helsinki.

2.2. Carbohydrate MA Testing. To detect individuals with primary adult-type lactose malabsorption, LCT genotyping (C/T\textsubscript{13910} Polymorphism) was performed [12]. VACUETTE® K3EDTA tubes (2 mL) (Greiner Bio-One International GmbH, Kremsmünster, Austria) were drawn from patients for genomic DNA extraction on a MagNA Pure Compact Instrument (Roche Diagnostics, Rotkreuz, Switzerland). Real-time PCR with specific fluorescent labelled hybridization probes, followed by a melting curve analysis (LCT T-13910C ToolSet™ (Roche Diagnostics)), was established on a LightCycler® 2.0 Instrument (Roche Diagnostics).

A fructose breath test protocol was established to detect patients with fructose malabsorption. Gas chromatography was employed to measure the H\textsubscript{2} and CH\textsubscript{4} concentration using a QuinTron Model DP Plus MicroLyzer™ (QuinTron, Milwaukee, WI, USA). After determining baseline breath H\textsubscript{2}/CH\textsubscript{4} concentrations, fructose was given in a dose of 25 g dissolved in 200 mL of water. The end-expiratory breath H\textsubscript{2}/CH\textsubscript{4} concentrations were measured at 15, 30, 45, 60, 75, 90, and 120 minutes after fructose ingestion. Patients were classified with fructose malabsorption, if a H\textsubscript{2} and/or CH\textsubscript{4} increase >20 ppm above baseline concentrations was observed [11, 12, 20].

2.3. Determination of Intestinal Biomarkers TMAO and Zonulin. Fasting blood samples were drawn into 4 mL VACUETTE® Z Serum Clot Activator tubes (Greiner Bio-One International GmbH, Kremsmünster, Austria). Serum samples were centrifuged at 1800 x g for 10 minutes and immediately analyzed. TMAO was measured using a stable-isotope-dilution assay and high-performance liquid chromatography (HPLC) with electrospray ionization tandem mass spectrometry on a SCIEX QTRAP 4500 triple quadrupole instrument (Applied Biosystems, Framingham, MA, USA) equipped with an Agilent 1260 Infinity HPLC system (Agilent Technologies, Santa Clara, CA, USA). The intra- and interday coefficients of variation (CVs) ranged between 2.2–5.5% and 7.6–9.9%, respectively.

The serum zonulin concentrations were measured with the IDK® enzyme linked immunovoltaassay (ELISA) (Immuno-diagnostic AG, Bensheim, Germany) according to the manufacturer’s recommendations. The intraday CVs were <8% and the interday CVs were <12%, respectively.

2.4. BDI-II Score. For the assessment of the presence and severity of depressive symptoms, we used the BDI-II score. This questionnaire consists of 21 items (scale: 0–3), and the total values range between 0 and 63 (21). According to the literature, individuals with a BDI-II score > 13 were classified with the presence of depressive symptoms [21, 22].
2.5. Statistical Analysis. Descriptive statistics were computed for the categorical and metric variables. The Kolmogorov-Smirnov test was performed to calculate data distribution. As continuous variables were not normally distributed, they were expressed as medians with interquartile ranges (Q1–Q3). Categorical variables were expressed as percentages. The exact Mann-Whitney U-test was performed for subgroup comparisons of nonnormal distributed metric variables. Spearman's rho (ρ) was calculated to assess possible positive or negative correlations between the intestinal biomarkers TMAO and zonulin and the BDI-II score. A P value of <0.05 was considered statistically significant. For all statistical analyses, the SPSS 25.0 statistical software (SPSS Inc., Chicago, IL, USA) was used.

3. Results

3.1. General Characteristics of the Study Population. The clinical and laboratory characteristics of the study population are shown in Table 1. The average age was 40.6 ± 14.5 years. Of all 251 study participants, 160 (63.7%) were female and 91 (36.3%) were male. In total, 115 (73 females and 42 males) (45.8%) patients were identified with CMA. Of these, 50 (19.9%) patients showed lactose malabsorption, 50 (19.9%) showed fructose malabsorption, and 15 (6%) were diagnosed with lactose and fructose malabsorption.

Sixty-five (56.5%) out of 115 individuals with CMA were C/C₁₃₉₁₀ homozygotes, the LCT genotype indicative of primary-adult lactose malabsorption, and 32 (27.8%) and 18 (15.7%) individuals could be identified as C/T₁₃₉₁₀ hetero- and T/T₁₃₉₁₀ homozygotes. The genotype frequencies for 136 non-CMA individuals were 86 (63.2%) for the C/T₁₃₉₁₀ and 50 (36.8%) for the T/T₁₃₉₁₀ genotype.

The median BDI-II score (interquartile ranges) was 10 (3–20). Overall, 155 (95 females and 60 males) (61.8%) and 96 (65 females and 31 males) (38.2%) individuals were found with a BDI-II score ≤ 13 and >13, respectively.

3.2. TMAO and Zonulin Measurements and BDI-II Score. The median TMAO and zonulin serum concentrations were 2.66 (1.93–4.14) μmol/L and 40.83 (34.73–47.48) ng/mL. The correlations of TMAO and zonulin with the BDI-II score are illustrated in Table 2. In the study population (n = 251), a positive correlation was observed between the TMAO and the BDI-II score (P = 0.011, ρ = 0.160). The serum TMAO concentrations were positively correlated with the BDI-II score in individuals with non-CMA (n = 136; P = 0.001, ρ = 0.277), both females (n = 87; P = 0.010, ρ = 0.274) and males (n = 49; P = 0.027, ρ = 0.315). The TMAO serum concentration comparison between 96 and 40 non-CMA individuals with a BDI-II score ≤ 13 and >13 is shown in Figure 1. Gender-specific TMAO level comparisons in females and males between BDI-II score ≤ 13 and >13 are illustrated in Figures 2 and 3.

Zonulin tended to be negatively correlated with the BDI-II score in males without CMA (n = 49; P = 0.062, ρ = −0.269).

Table 1: Baseline characteristics of the study population (n = 251).

| Characteristic                  | Baseline                        |
|--------------------------------|--------------------------------|
| Age (yr)                       | 40.6 ± 14.5                    |
| Sex                            |                                |
| Female                         | 160 (63.7%)                    |
| Male                           | 91 (36.3%)                     |
| Carbohydrate malabsorption     |                                |
| Lactose malabsorber            | 65 (25.9%)                     |
| Fructose malabsorber           | 65 (25.9%)                     |
| Nonmalabsorber                 | 136 (54.2%)                    |
| Laboratory parameters          |                                |
| TMAO (μmol/L)                  | 2.66 (1.93–4.14)               |
| Zonulin (ng/mL)                | 40.83 (34.73–47.48)            |
| Depressive symptoms            |                                |
| BDI-II score                   | 10 (3–20)                      |

BDI-II: Beck Depression Inventory. Data are presented as means ± standard deviation, or medians (Q1–Q3), or percentage.

3.3. Correlations of BMI with Zonulin and TMAO. There was a positive correlation between BMI and zonulin (all patients: P < 0.001, ρ = 0.266; females: P = 0.003, ρ = 0.238; males: P = 0.004, ρ = 0.302). No statistically relevant correlation was observed between BMI and TMAO.

4. Discussion

In the current work, we investigated 251 ambulatory individuals, who were primarily referred for CMA testing to our outpatient clinic for possible gender-specific associations between TMAO and zonulin concentrations and the BDI-II score. To the best of our knowledge, this is the first study addressing this intestinal biomarker profile in individuals with and without CMA. We found a significantly positive correlation for TMAO serum concentrations and the severity of depressive symptoms (P = 0.011, ρ = 0.160). The strongest association was observed in males without CMA (P = 0.027, ρ = 0.315) followed by females without CMA (P = 0.010, ρ = 0.274), whereas individuals with CMA showed no significant correlations.

In comparison, a previously published study by Liu et al., in which 16 depressed patients and 16 healthy subjects were recruited, reported significantly higher (P < 0.05) TMAO blood levels in the depressed group compared to the healthy control group [23]. The studied patient groups were too small for the assessment of possible gender-specific differences. Another previous study indicated that depressed individuals have an altered gut microbiome metabolism, including concentration changes of metabolites, such as dimethylamine, dimethylglycine, and TMAO [16].

These findings emphasize the potential influence of the gut microbiome in the development of depression. However, the exact pathophysiological mechanism of the gut-brain axis cannot be fully explained yet. The gut microbiota-derived TMAO needs to pass the GBB, which is a complex intestinal multilayer system regulating the absorption of water and...
nutrients [6]. Since TMAO was shown to be present in human cerebrospinal fluid [24], it is hypothesized that TMAO could have the potential to cross the BBB [25]. These findings are indicative that TMAO could play a direct role in the central nervous system [24].

Here, correlations between TMAO and the BDI-II score differed between CMA and non-CMA. CMA is known as a gastrointestinal condition associated with changes of the gut microbiome composition and leaky intestinal barrier function [26–28]. This could be a potential explanation for the various correlations between TMAO blood levels and depressive symptoms found here. Present data also indicate distinctive gender-specific differences between the relationship of TMAO and depressive symptoms with strongest associations found in males without CMA.

In males without CMA, serum zonulin levels tended to be negatively correlated with depressive symptoms (\(P = 0.062, \rho = -0.269\)). Recently, Ohlsson et al. showed that depressive symptoms correlated negatively at trend with zonulin blood concentrations (\(P = 0.07, r = -0.21\)) [29]. However, differences in the study designs and participants must be mentioned: Ohlsson et al. compared 54 individuals with recent suicide attempts with 13 subjects with major depressive disorders and no history of a suicide attempt and 17 healthy controls. For the assessment of depressive symptoms, the authors used the Montgomery-Åsberg Depression Rate Scale (MADRS) [29]. In contrast, we assessed depressive symptoms with the BDI-II score in 115 and 136 individuals with and without CMA and additionally considered gender-specific variations.
Our data suggest that serum zonulin levels in males may represent a different pattern of gut integrity compared to females. A recently published study showed that zonulin has the potential to enhance the permeability of both the GBB and the BBB [30]. Zonulin causes a dysregulation of the endothelial tight junctions of these barriers [10]. As a consequence of the altered permeability, the development of depressive symptoms may be triggered by microbiota-derived degradation products (i.e., neurotransmitters, TMAO, and toxic bacterial metabolites) [31].

Nevertheless, it must be mentioned that the measurement of serum zonulin as a biomarker of leaky gut with currently commercially available ELISA kits is limited because of the lack of protein specificity of monoclonal capture antibodies [32, 33].

Two limitations of this study may be described. Firstly, this study is cross-sectional in nature, representing serum TMAO and zonulin assessment at a measuring single point, only. Secondly, secondary acquired and reversible forms of lactose malabsorption were not identified because the lactose H₂/CH₄ breath test was not performed in this study.

5. Conclusions

In conclusion, females and males without CMA showed a positive correlation of serum TMAO concentrations and the severity of depressive symptoms. Serum zonulin concentrations were negatively correlated in males without CMA. These findings are indicative of a sex-specific link between the intestinal biomarkers TMAO and zonulin and depressive symptoms in individuals without malabsorption. However, the authors suggest performing further prospective longitudinal studies to fully elucidate the relationship between sex-specific differences of the TMAO and zonulin pattern, CMA and depressive disorders.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

SM, AB, SH, WJS, SZ, HM, MH, AM, and DE designed and conducted the study. SM, WJS, AM, and DE collected data. SM, AM, and DE analyzed and interpreted data. SM and DE wrote the manuscript. DE supervised the study. All listed authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

References

[1] M. Carabotti, A. Scirocchi, M. A. Maselli, and C. Severi, “The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems,” Annals of Gastroenterology, vol. 28, no. 2, pp. 203–209, 2015.
[2] N. M. Vogt, K. A. Romano, B. F. Darst et al., “The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease,” Alzheimer’s Research & Therapy, vol. 10, no. 1, p. 124, 2018.
[3] F. Meng, N. Li, D. Li, B. Song, and L. Li, “The presence of elevated circulating trimethylamine N-oxide exaggerates postoperative cognitive dysfunction in aged rats,” Behavioural Brain Research, vol. 368, p. 111902, 2019.
[4] W. H. Tang, Z. Wang, B. S. Levison et al., “Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk,” The New England Journal of Medicine, vol. 368, no. 17, pp. 1575–1584, 2013.
[5] B. J. Bennett, T. Q. de Aguiar Vallim, Z. Wang et al., “Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation,” Cell Metabolism, vol. 17, no. 1, pp. 49–60, 2013.
[6] M. Ufnal and K. Pham, “The gut-blood barrier permeability – a new marker in cardiovascular and metabolic diseases?,” Medical Hypotheses, vol. 98, pp. 35–37, 2017.
[7] W. Wang, S. Uzzau, S. E. Goldblum, and A. Fasano, “Human zonulin, a potential modulator of intestinal tight junctions,” Journal of Cell Science, vol. 113, no. 24, pp. 4435–4440, 2000.
[8] J. M. Moreno-Navarrete, M. Sabater, F. Ortega, W. Ricart, and J. M. Fernández-Real, “Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance,” PLoS One, vol. 7, no. 5, p. e37160, 2012.
[9] M. Camilleri, K. Madsen, R. Spiller, B. Greenwood-Van Meerveld, and G. N. Verne, “Intestinal barrier function in health and gastrointestinal disease,” Neurogastroenterology and Motility, vol. 24, no. 6, pp. 503–512, 2012.
[10] C. Sturgeon and A. Fasano, “Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases,” Tissue Barriers, vol. 4, no. 4, p. e1251384, 2016.
[11] A. Eisenmann, A. Amann, M. Said, B. Datta, and M. Ledochowski, “Implementation and interpretation of hydrogen breath tests,” Journal of Breath Research, vol. 2, no. 4, p. 046002, 2008.
[12] D. Enko, E. Rezanka, R. Stolba, and G. Halwachs-Baumann, “Lactose Malabsorption Testing in Daily Clinical Practice: A Critical Retrospective Analysis and Comparison of the Hydrogen/Methane Breath Test and Genetic Test (Polymorphism) Results,” Gastroenterology Research and Practice, vol. 2014, Article ID 464382, 6 pages, 2014.
[13] R. J. Johnson, C. Rivard, M. A. Lanasa et al., “Fructokinase, fructans, intestinal permeability, and metabolic syndrome: an equine connection?,” Journal of Equine Veterinary Science, vol. 33, no. 2, pp. 120–126, 2013.
[14] M. Ledochowski, B. Widner, B. Sperrer-Unterweger, T. Propst, W. Vogel, and D. Fuchs, “Carbohydrate malabsorption syndromes and early signs of mental depression in females,” Digestive Diseases and Sciences, vol. 45, no. 7, pp. 1255–1259, 2000.
[15] D. Enko, H. Wagner, G. Kriegshäuser et al., “Assessment of tryptophan metabolism and signs of depression in individuals with carbohydrate malabsorption,” Psychiatry Research, vol. 262, pp. 595–599, 2018.
[16] P. Zheng, Y. Wang, L. Chen et al., “Identification and validation of urinary metabolite biomarkers for major depressive
disorder,” *Molecular & Cellular Proteomics*, vol. 12, no. 1, pp. 207–214, 2012.

[17] J. S. Tian, G. J. Peng, X. X. Gao et al., “Dynamic analysis of the endogenous metabolites in depressed patients treated with TCM formula Xiaoyaosan using urinary $^1$H NMR-based metabolomics,” *Journal of Ethnopharmacology*, vol. 158, pp. 1–10, 2014.

[18] B. R. Stevens, R. Goel, K. Seungbum et al., “Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression,” *Gut*, vol. 67, no. 8, pp. 1555–1557, 2018.

[19] R. A. Steer, R. Ball, W. F. Ranieri, and A. T. Beck, “Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients,” *Journal of Clinical Psychology*, vol. 55, no. 1, pp. 117–128, 1999.

[20] D. Enko, G. Kriegshäuser, C. Kimbacher, R. Stolba, H. Mangge, and G. Halwachs-Baumann, “Carbohydrate malabsorption and putative carbohydrate-specific small intestinal bacterial overgrowth: prevalence and diagnostic overlap observed in an Austrian outpatient center,” *Digestion*, vol. 92, no. 1, pp. 32–38, 2015.

[21] A. T. Beck, R. A. Steer, and G. K. Brown, *Manual for the Beck Depression Inventory-II*, Psychological Corporation, San Antonio, TX, 1996.

[22] K. L. Smarr and A. L. Keefer, “Measures of depression and depressive symptoms: Beck depression Inventory-II (BDI-II), center for epidemiologic studies depression scale (CES-D), geriatric depression scale (GDS), hospital anxiety and depression scale (HADS), and patient health Questionnaire,” *Arthritis Care & Research*, vol. 63, no. S11, pp. S454–S466, 2011.

[23] C. C. Liu, Y. F. Wu, G. M. Feng et al., “Plasma-metabolite-biomarkers for the therapeutic response in depressed patients by the traditional Chinese medicine formula Xiaoyaosan: A $^1$H NMR-based metabolomics approach,” *Journal of Affective Disorders*, vol. 185, pp. 156–163, 2015.

[24] D. Del Rio, F. Zimetti, P. Caffarra et al., “The gut microbial metabolite trimethylamine-N-oxide is present in human cerebrospinal fluid,” *Nutrients*, vol. 9, no. 10, p. 1053, 2017.

[25] L. Vernetti, A. Gough, N. Baetz et al., “Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney, Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle,” *Scientific Reports*, vol. 7, no. 1, 2017.

[26] D. Simeonova, M. Ivanovska, M. Mundjeva, A. F. Carvalho, and M. Maes, “Recognizing the leaky gut as a trans-diagnostic target for neuroimmune disorders using clinical chemistry and molecular immunology assays,” *Current Topics in Medicinal Chemistry*, vol. 18, no. 19, pp. 1641–1655, 2018.

[27] A. Spruss, G. Kanuri, C. Stahl, S. C. Bischoff, and I. Bergheim, “Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function,” *Laboratory Investigation*, vol. 92, no. 7, pp. 1020–1032, 2012.

[28] Y. E. Cho, D. K. Kim, W. Seo, B. Gao, S. H. Yoo, and B. J. Song, “Fructose promotes leaky gut, Endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P-450-2E1–mediated oxidative and nitrative stress,” *Hepatology*, 2019.

[29] L. Ohlsson, A. Gustafsson, E. Lavant et al., “Leaky gut biomarkers in depression and suicidal behavior,” *Acta Psychiatrica Scandinavica*, vol. 139, no. 2, pp. 185–193, 2019.

[30] M. T. Rahman, C. Ghosh, M. Hossain et al., “IFN-$\gamma$, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases,” *Biochemical and Biophysical Research Communications*, vol. 507, no. 1–4, pp. 274–279, 2018.

[31] G. Morris, B. S. Fernandes, B. K. Puri, A. J. Walker, A. F. Carvalho, and M. Berk, “Leaky brain in neurological and psychiatric disorders: drivers and consequences,” *The Austral-ian and New Zealand Journal of Psychiatry*, vol. 52, no. 10, pp. 924–948, 2018.

[32] M. Ajamian, D. Steer, G. Rosella, and P. R. Gibson, “Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems,” *PLoS One*, vol. 14, no. 1, p. e0210728, 2019.

[33] F. Valitutti and A. Fasano, “Breaking down barriers: how understanding celiac disease pathogenesis informed the development of novel treatments,” *Digestive Diseases and Sciences*, vol. 64, no. 7, pp. 1748–1758, 2019.